TITLE

CURRENT AND FUTURE PHARMACOTHERAPY FOR THE OVERACTIVE BLADDER

AUTHOR(S)
Hijaz, Adonis; Vasavada, Sandip; Rackley, Raymond
PUB. DATE
June 2005
SOURCE
Contemporary Urology;Jun2005, Vol. 17 Issue 6, p48
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Pharmacologic therapy for the treatment of OAB is currently based on our understanding of the mechanisms involved in the micturition process. As our knowledge continues to expand in this area, patients are sure to benefit from our ability to develop agents that act on the elaborate interactions of the bladder smooth muscle, efferent motor nerves, afferent sensory nerves, and the CNS. Antimuscarinic drugs are the only pharmacologic agents that have demonstrated proof of concept in humans; however, the lack of bladder specificity is the greatest drawback of this class of agents based on the distribution of muscarinic receptors throughout the body. To reduce the burden of "off-target" organ muscarinic-receptor binding as a means of minimizing adverse events from nonselective muscarinic agents, newly introduced M3-selective agents are showing proof of concept in outcomes from randomized controlled trials. The promise for future therapies to treat primary OAB resides in the ability to produce bladder or "target organ"-specific agents through pharmacokinetics or physical (instillation or injection) properties that address individual or combination mechanisms that contribute to the micturition reflex. INSET: UROlogic.
ACCESSION #
17312115

 

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics